Sutro Biopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Sutro Biopharma announces its 2026 Annual Meeting of Shareholders, scheduled for June 5th, to elect directors, ratify auditors, and vote on executive compensation.
NASDAQ
Sutro Biopharma's upcoming annual meeting includes proposals for director elections, auditor ratification, executive compensation approval, and a potential reverse stock split.
NASDAQ
Sutro Biopharma announces its 2025 Annual Meeting of Shareholders to be held virtually on June 6, 2025, including proposals for director elections, auditor ratification, executive compensation approval, and a potential reverse stock split.
NASDAQ
Sutro Biopharma issued a supplement to its proxy statement to correct a typographical error regarding the deadline for stockholders to submit proposals for the 2025 annual meeting.
NASDAQ
Sutro Biopharma announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, featuring proposals for director elections, auditor ratification, executive compensation, and ESPP amendment.
NASDAQ
DEFA14A: Sutro Biopharma Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Shareholder Vote
Sutro Biopharma's upcoming annual meeting on June 6, 2024, will address the election of directors, ratification of Ernst & Young LLP as the accounting firm, executive compensation, and an amendment to the Employee Stock Purchase Plan.